BCM
CLPT icon

Boone Capital Management’s ClearPoint Neuro CLPT Stock Holding History

Boone Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-283,912
Closed -$6.19M – 17
2025
Q3 		$6.19M Buy
+283,912
New +$3.34M 2.03% 15

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
FCM
FirstWave Capital Management Miami, Florida $94.1M AUM
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Boone Capital Management's CLPT Position: Q4 2025 in Review

Boone Capital Management sold out of ClearPoint Neuro (CLPT) in Q4 2025, closing a stake of 283,912 shares — an estimated $6.19M sold.

Boone Capital Management first reported a position in CLPT in Q3 2025 and held it in 1 quarter. The position peaked at $6.19M in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q4 2025.

  • Boone Capital Management reported no remaining ClearPoint Neuro position as of Q4 2025 after selling out during the quarter.
  • Boone Capital Management sold 283,912 ClearPoint Neuro shares in Q4 2025, an estimated $6.19M.
  • Boone Capital Management first reported a position in ClearPoint Neuro in Q3 2025 and held it in 1 quarter.
  • Boone Capital Management's ClearPoint Neuro position peaked at $6.19M in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2025.

Based on Boone Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.